Valuation: Delcath Systems, Inc.

Market Cap 45Cr 40Cr 37Cr 34Cr 64Cr 4.37TCr 65Cr 434.82Cr 170.75Cr 2.13TCr 170.32Cr 166.59Cr 7.35TCr P/E 2026 *
-23.2x
P/E 2027 * -24.4x
Enterprise Value 45Cr 40Cr 37Cr 34Cr 64Cr 4.37TCr 65Cr 434.82Cr 170.75Cr 2.13TCr 170.32Cr 166.59Cr 7.35TCr EV / Sales 2026 *
4.39x
EV / Sales 2027 * 3.47x
Free-Float
91.87%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/10/2020
Director of Finance/CFO 47 01/05/2023
Compliance Officer 56 25/01/2022
Director TitleAgeSince
Director/Board Member 62 01/10/2020
Director/Board Member 70 14/02/2020
Director/Board Member 60 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.34%-2.21%+0.19%-28.68% 2.04TCr
+1.37%-0.10%-9.87%-13.27% 1.5TCr
+0.65%-2.40%-58.83%-46.17% 563.04Cr
+8.03%+3.86% - - 364.65Cr
-0.38%-2.22%-18.77%-18.39% 172.91Cr
+2.39%-1.38%+36.79%+9.64% 159.93Cr
-1.21%+9.23%-38.55%-60.33% 122.47Cr
+6.35%+10.32%+79.91%+142.90% 86Cr
+5.77%-5.91% - - 25Cr
Average +2.59%-1.25%-1.30%-2.04% 560.21Cr
Weighted average by Cap. +1.37%-2.14%-9.19%-21.77%

Financials

2026 *2027 *
Net sales 10Cr 9Cr 8.31Cr 7.63Cr 14Cr 993.65Cr 15Cr 99Cr 39Cr 485.37Cr 39Cr 38Cr 1.67TCr 13Cr 11Cr 11Cr 9.65Cr 18Cr 1.26TCr 19Cr 125.22Cr 49Cr 614.13Cr 49Cr 48Cr 2.12TCr
Net income -2.1Cr -1.84Cr -1.69Cr -1.55Cr -2.95Cr -202.54Cr -3Cr -20Cr -7.92Cr -99Cr -7.9Cr -7.73Cr -341.17Cr -2Cr -1.74Cr -1.61Cr -1.48Cr -2.81Cr -192.52Cr -2.86Cr -19Cr -7.53Cr -94Cr -7.51Cr -7.35Cr -324.29Cr
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-